Dried blood spot analysis of an iron chelator - Deferasirox and its potential application to therapeutic drug monitoring

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 907, Issue , 2012, Pages 65-73

  Nirogi, Ramakrishna ^a   Ajjala, Devender Reddy ^a   Kandikere, Vishwottam ^a   Aleti, Raghupathi ^a   Srikakolapu, SuryaRao ^a   Vurimindi, Himabindu ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Deferasirox; Dried blood spot (DBS); FTA DMPK C; Iron chelator; Iron overload; Liquid chromatography tandem mass spectrometry

Indexed keywords

DEFERASIROX; DRIED BLOOD SPOTS; FTA-DMPK-C; IRON CHELATORS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY;

CHELATION; DRUG PRODUCTS; IRON; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; PATIENT MONITORING; PATIENT TREATMENT;

BLOOD;

DEFERASIROX; FLUINDOSTATIN;

ACCURACY; ANIMAL TISSUE; ARTICLE; BLOOD; BLOOD SAMPLING; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG EFFICACY; DRUG MONITORING; LINEAR SYSTEM; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RAT; REVERSED PHASE LIQUID CHROMATOGRAPHY;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BENZOATES; CHROMATOGRAPHY, LIQUID; DRIED BLOOD SPOT TESTING; DRUG MONITORING; DRUG STABILITY; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; IRON CHELATING AGENTS; LINEAR MODELS; MALE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TRIAZOLES;

ANIMALIA; RATTUS;

EID: 84867397235     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.08.036     Document Type: Article

References (35)

1. Beaudette P., Batemann K.P. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2004, 809:153-158.
2. Barfield M., Spooner N., Lad R., Parry S., Fowles S. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 870:32-37.
3. Liang X., Li Y., Barfield M., Ji Q.C. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:799-806.
4. Spooner N., Lad R., Barfield M. Anal. Chem. 2009, 81:1557-1563.
5. Barfiled M., Wheller R. Anal. Chem. 2011, 83:118-124.
6. Parker S.P., Cubitt W.D. J. Clin. Pathol. 1999, 52:633-639.
7. Chase D.H., Adam B.W., Smith S.J., Alexander J.R., Hillman S.L., Hannon W.H. Clin. Chem. 1999, 45:1269-1277.
8. Fan L., Lee J.A. Bioanalysis 2012, 4:345-347.
9. Li W., Tse L.S. Biomed. Chromatogr. 2010, 24:49-65.
10. Vu D.H., Koster R.A., Alffenaar J.W.C., Brouvers J.R.B.J., Uges D.R.A. J. Chromatogr. B 2011, 879:1063-1070.
11. Denniff P., Spooner N. Bioanalysis 2010, 8:1385-1395.
12. Youhnovski N., Bergeron A., Furtado M., Garofolo F. Rapid Commun. Mass Spectrom. 2011, 19:2951-2958.
13. Peng M., Liu L., Peng L. Clin. Chim. Acta 2012, 413:1265-1269.
14. Li F., Ploch S., Fast D., Michael S. J. Mass Spectrom. 2012, 47:655-667.
15. Britton R.S., Leicester K.L., Bacon B.R. Int. J. Hematol. 2002, 76:219-228.
16. Schrier S.L., Angelucci E. Annu. Rev. Med. 2005, 56:157-171.
17. Taher A. Semin. Hematol. 2005, 42:S5-S9.
18. Rund D., Rachmilewitz E. N. Engl. J. Med. 2005, 353:1135-1146.
19. Bruin G.J.M., Thomas F., Hansjorg W., Alain S., Hanspeter N., Schneider S., Olaf B.K., Felix W. Drug Metab. Dispos. 2008, 36:2523-2538.
20. (accessed 8.8.2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf.
21. (accessed 8.8.2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf.
22. Galanello R., Piga A., Alberti D. J. Clin. Pharmacol. 2003, 43:565-572.
23. Galanello R., Campus S., Origa R. Expert Opin. Drug Metab. Toxicol. 2012, 8:123-134.
24. Iyer L., Das S., Janisch L., Wen M., Ramirej J., Karrison T., Flemming G.F., Vokes E.E., Schilsky R.L., Ratain M.J. Pharmacog. J. 2002, 2:43-47.
25. Marquet P., Rousseau A. Bull. Cancer 2008, 95:903-909.
26. Rouan M.C., Marfil F., Mangoni P., Sechaud R., Humbert H., Maurer G. J. Chromatogr. B 2001, 755:203-213.
27. Rouan M.C., Buffer C., Masson L., Marfil F., Humbert H., Maurer G. J. Chromatogr. B 2001, 754:45-55.
28. De Francia S., et al. J. Chromatogr. B 2012, 10.1016/j.jchromb.2012.02.047.
29. Sechuad R., Anna R., Rosella B., Sebastien B. J. Clin. Pharmacol. 2008, 48:919-925.
30. Emmanuelle C., Stephane B., Marguerite M., Francois X.M., Nicholas M., Karine T., Mathieu M. Ther. Drug Monit. 2010, 32:476-481.
31. Pligoropoulu H., et al. J. Chromatogr. B 2012, 10.1016/j.jchromab.2012.02.044.
32. Martin Smith R. Understanding the Mass Spectra 2004, Wiley-Interscience, p. 106. 2nd ed.
33. Potts K.T., Ambruster R., Iloughton E. J. Heterocycl. Chem. 1971, 8:773-777.
34. Xiaohui C., Hongjuan Z., Panos H., Jakal A. J. Chromatogr. B 2012, 61:30-37.
35. U.S. Department of Health and Human Services, FDA, CDER, CVM Guidance for Industry - Bioanalytical Method Validation 2001, Center for Drug Evaluation and Research (CDER), Rockville.